top of page

Beware of a hiring scam. Fraudsters are posing as our HR staff. They are conducting interviews via chat services. If you are contacted for an interview without having applied to the company, please ignore the solicitation. It is a scam.

Brain-Pills.png

Praetego’s PTG-630 Successfully Completes a Pre-IND Meeting with the FDA’s Division of Neurology

Writer's picture: PraetegoPraetego

Praetego successfully completed a Pre-IND meeting with the FDA’s Division of Neurology for PTG-630 to limit early Alzheimer’s disease. The FDA review team agreed to the IND-enabling plan as proposed, thus confirming the suitability of PTG-630’s pathway to clinical readiness. Praetego is excited to initiate the necessary studies to prepare for an IND and be in clinic in 2025. PTG-630 has the potential to be an ideal drug candidate to protect patients from disease progression in Alzheimer’s disease.

bottom of page